Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Foam, 0.05%, a generic version of Olux1 Foam, 0.05%, of Mylan Pharmaceuticals, Inc.
According to IQVIA sales data for the 12 month period ending December 2018, the Olux Foam, 0.05% market2 achieved annual sales of approximately $50.9 million
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
